Mirae Asset Global Investments Co. Ltd. Decreases Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

Mirae Asset Global Investments Co. Ltd. trimmed its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 12.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,940 shares of the company’s stock after selling 3,491 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Henry Schein were worth $1,888,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in HSIC. Cambridge Investment Research Advisors Inc. raised its position in shares of Henry Schein by 2.4% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 5,262 shares of the company’s stock valued at $459,000 after buying an additional 122 shares during the last quarter. Aurora Investment Counsel raised its position in shares of Henry Schein by 0.7% in the third quarter. Aurora Investment Counsel now owns 20,641 shares of the company’s stock valued at $1,533,000 after buying an additional 140 shares during the last quarter. Arizona State Retirement System raised its position in shares of Henry Schein by 0.4% in the fourth quarter. Arizona State Retirement System now owns 35,890 shares of the company’s stock valued at $2,717,000 after buying an additional 149 shares during the last quarter. Studio Investment Management LLC raised its position in shares of Henry Schein by 3.9% in the fourth quarter. Studio Investment Management LLC now owns 4,160 shares of the company’s stock valued at $332,000 after buying an additional 155 shares during the last quarter. Finally, Kentucky Retirement Systems Insurance Trust Fund raised its position in shares of Henry Schein by 3.4% in the third quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 4,878 shares of the company’s stock valued at $321,000 after buying an additional 161 shares during the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on HSIC. Evercore ISI raised their price objective on shares of Henry Schein from $79.00 to $83.00 and gave the stock an “in-line” rating in a research report on Wednesday, February 28th. SVB Leerink began coverage on shares of Henry Schein in a research report on Monday, February 26th. They set a “market perform” rating and a $78.00 price objective for the company. Jefferies Financial Group raised their price objective on shares of Henry Schein from $74.00 to $81.00 and gave the stock a “hold” rating in a research report on Wednesday, March 6th. JPMorgan Chase & Co. raised their price objective on shares of Henry Schein from $82.00 to $88.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. Finally, Piper Sandler raised their price objective on shares of Henry Schein from $78.00 to $86.00 and gave the stock an “overweight” rating in a research report on Monday, February 26th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Henry Schein presently has a consensus rating of “Hold” and a consensus price target of $81.09.

Insider Transactions at Henry Schein

In other news, Vice Chairman James P. Breslawski sold 2,907 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $74.37, for a total transaction of $216,193.59. Following the completion of the sale, the insider now owns 209,562 shares in the company, valued at approximately $15,585,125.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Henry Schein news, CEO Bradford C. Connett sold 6,430 shares of the business’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total value of $477,620.40. Following the transaction, the chief executive officer now directly owns 73,108 shares of the company’s stock, valued at approximately $5,430,462.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the business’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $74.37, for a total transaction of $216,193.59. Following the completion of the transaction, the insider now directly owns 209,562 shares in the company, valued at $15,585,125.94. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Henry Schein Price Performance

Shares of HSIC opened at $70.86 on Friday. Henry Schein, Inc. has a 1-year low of $60.01 and a 1-year high of $85.39. The stock has a market cap of $9.10 billion, a PE ratio of 22.50, a P/E/G ratio of 1.74 and a beta of 0.87. The firm has a 50-day simple moving average of $74.37 and a two-hundred day simple moving average of $72.47. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.67 and a quick ratio of 1.00.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $0.66 EPS for the quarter, missing the consensus estimate of $0.70 by ($0.04). Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. The business had revenue of $3.02 billion during the quarter, compared to analysts’ expectations of $3 billion. During the same period in the previous year, the business posted $1.21 EPS. The company’s revenue for the quarter was down 10.5% compared to the same quarter last year. As a group, analysts forecast that Henry Schein, Inc. will post 5.07 EPS for the current year.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.